Loading patent…
AssigneeKAI Pharmaceuticals, Inc.
InventorsFelix Karim, Amos Baruch, Derek Maclean, Kanad Das, Qun Yin
Estimating the term…
Compounds having activity for lowering parathyroid hormone levels are described. In one embodiment, the compounds are comprised of a contiguous sequence of subunits, X1-X2-X3-X4-X5-X6-X7, wherein the X1 subunit comprises a thiol-containing moiety and the distribution of charge on the X2-X7 subunits provides the desired activity. Methods of using the compounds for treating hyperparathyroidism, bone disease and/or hypercalcemic disorders are also described, and in particular, methods for lowering plasma PTH and serum calcium are provided. The compounds can be used to treat subjects having, for example: primary, secondary or tertiary hyperparathyroidism; hypercalcemia of malignancy; metastatic bone disease; or osteoporosis.
A conjugate, comprising a peptide and a conjugating group, wherein the peptide comprises the amino acid sequence carrrar (SEQ ID NO:2), and wherein the peptide is linked to the conjugating group by a disulfide bond.
A method of treating secondary hyperparathyroidism (SHPT) in a subject, comprising administering to the subject a therapeutically effective amount of a conjugate comprising a peptide and a conjugating group, wherein the peptide comprises the amino acid sequence carrrar (SEQ ID NO:2), and wherein the peptide is linked to the conjugating group by a disulfide bond.
A method of decreasing parathyroid hormone levels in a subject, comprising administering to the subject an amount of a conjugate comprising a peptide and a conjugating group, wherein the peptide comprises the amino acid sequence carrrar (SEQ ID NO:2), and wherein the peptide is linked to the conjugating group by a disulfide bond.
A method for treating a subject, comprising administering to the subject (i) a conjugate comprising a peptide and a conjugating group, wherein the peptide comprises the amino acid sequence carrrar (SEQ ID NO:2), and wherein the peptide is linked to the conjugating group by a disulfide bond and (ii) a second therapeutic agent.
Dependencies are inferred from the claim text.